Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Ganitumab, an Investigational Fully Human Monoclonal Antibody to Insulin-like Growth Factor Type 1 Receptor, Combined with Gemcitabine as First-line Therapy in Patients with Metastatic Pancreatic Cancer: A Phase 1b Study

Takuji Okusaka, Masafumi Ikeda, Akira Fukutomi, Yoshikazu Kobayashi, Kazuhiro Shibayama, Takatoshi Takubo, Jennifer Gansert
2014 Japanese Journal of Clinical Oncology  
Objective: Previous Phase 1 studies have shown the acceptable safety profile of ganitumaba fully human monoclonal antibody to insulin-like growth factor Type 1 receptor-in patients with advanced solid tumors. However, ganitumab 20 mg/kg in combination with gemcitabine had not been administered to patients with metastatic pancreatic cancer. To evaluate the safety, tolerability, pharmacokinetics and antitumor activity of ganitumab 20 mg/kg combined with gemcitabine 1000 mg/m 2 as first-line
more » ... y in patients with metastatic pancreatic cancer, we conducted a Phase 1b study. Methods: Eligible patients were adults with previously untreated metastatic adenocarcinoma of the pancreas. Patients received gemcitabine 1000 mg/m 2 on Days 1, 8 and 15 plus ganitumab 20 mg/kg on Days 1 and 15 of each 28-day cycle. Gemcitabine was administered intravenously over 30 -60 min. Ganitumab was administered intravenously over 60 min after completing gemcitabine infusion. Results: Six patients were enrolled and received the study treatment. All patients had thrombocytopenia and leukopenia. Other most common adverse events were neutropenia and nausea. One patient had a dose-limiting toxicity defined as Grade 3 neutropenia with fever. Exposure to ganitumab 20 mg/kg was not affected by the administration of gemcitabine. No apparent pharmacokinetic drug -drug interaction was observed. No anti-ganitumab antibodies were detected. Five patients had a measurable tumor region at baseline. Of these, four patients had a best response of stable disease. Conclusions: Ganitumab 20 mg/kg combined with gemcitabine 1000 mg/m 2 was tolerable and showed an acceptable safety profile in patients with untreated metastatic pancreatic cancer.
doi:10.1093/jjco/hyu034 pmid:24782485 fatcat:3vt5rejwxreaza4jx2tyqmphqu